Skip to content

Effect of EMG biofeedback in the management of knee ligament injury

Efficacy of electromyography biofeedback in management of partial anterior cruciate ligament tear in comparison to conservative management alone: a randomized controlled trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/06/088245
Enrollment
82
Registered
2025-06-04
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S835- Sprain of cruciate ligament of knee

Interventions

Intervention1: Group A- EMG biofeedback + Conservative management for patients with partial ACL tear: Electromyography biofeedback (EMG-BFB) is a method that monitors muscular electrical activity, pr

Sponsors

Dr Bhaskar Mazumdar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. MRI confirmed post-traumatic partial ACL (Grade II) tear 2. Patients should be having clinical features suggestive of partial ACL tear, positive in Lachman test and Pivot shift test 3. Duration of injury less than 3 months 4. Pain with VAS score of more than or equals to 5 5. Patient willing to opt for non-surgical management for partial ACL tear

Exclusion criteria

Exclusion criteria: 1. MRI confirmed complete ACL tear 2. Multi-ligamentous knee injury 3. Presence of associated meniscal or chondral injury confirmed by MRI 4. Bilateral Knee involvement 5. Previous knee injuries and surgeries 6. Inflammatory causes of knee pain 7. Knee joint contracture 8. Local site infection 9. Coagulopathy 10. Any neuromuscular deficit in bilateral lower limbs 11. uncontrolled medical illness 12. Presence of red flag signs (Recent trauma, Fever, Fractures, Malignancy) 13. Patient refusal

Design outcomes

Primary

MeasureTime frame
Increase in Peak torque/Body weight(PT/BW) ratio of knee flexor and extensor muscles Timepoint: Baseline, 4 weeks, 8 weeks and 12 weeks

Secondary

MeasureTime frame
1. Increase in mean Agonist/Antagonist ratio 2. Decrease in pain (by VAS)Timepoint: Baseline, 4 weeks, 8 weeks and 12 weeks

Countries

India

Contacts

Public ContactDr Firdaus Kamal

IPGMER and SSKM Hospital

kamal.firdaus.kamal@gmail.com9830219554

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026